Our Science – Arch Biopartners

🌐 Cardiac surgery demand exceeds global capacity 12-to-1 (June 2024 - doi.org/10.1016/j.atssr.2023.11.019).

As access grows, so does the burden of CS-AKI—and the need for prevention.

📖 Learn more: archbiopartners.com/our-science

#ArchBiopartners #CSAKI #TrialRationale #ArchScience #InvestorFAQ

Contact Us – Arch Biopartners

📢 Long-format versions of Arch's posts are shared on LinkedIn (dub.sh/arch-linkedin).

Bluesky posts are mirrored on X (@archbiopartners).

Please follow, like and share to help expand reach.

📧 Prefer email? Subscribe here: archbiopartners.com/contact-us

#ArchBiopartners #InvestorFAQ #ArchNews

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.2 billion for Septerna, they said on Wednesday.

📢 Novo Nordisk & Septerna announce a $2.2B licensing deal.

"...developing a broad pipeline across various targets and modalities, including peptides and small molecules" – CSO Marcus Schindler

📖 Reuters dub.sh/novob-sepn-c...
📧 Email Alerts: archbiopartners.com/contact-us
#BiotechNews #InvestorFAQ

📢 Arch Biopartners’ May 2025 Corporate Presentation –Covers the CS-AKI and PONTiAK Phase II trials targeting inflammation- and toxin-related AKI.
📽️ Download the presentation and subscribe for updates at the Arch Investor Hub: www.archbiopartners.com/investor-hub/
#ArchBiopartners #CSAKI #InvestorFAQ